Candriam S.C.A. raised its holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) by 11.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 759,513 shares of the company’s stock after purchasing an additional 80,029 shares during the period. Candriam S.C.A.’s holdings in Olema Pharmaceuticals were worth $11,324,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Y Intercept Hong Kong Ltd boosted its holdings in Olema Pharmaceuticals by 143.0% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 90,375 shares of the company’s stock worth $1,347,000 after buying an additional 53,176 shares during the period. Fideuram Intesa Sanpaolo Private Banking S.P.A. raised its holdings in Olema Pharmaceuticals by 3,237.5% during the 1st quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 116,812 shares of the company’s stock valued at $1,742,000 after acquiring an additional 113,312 shares during the period. Virtu Financial LLC bought a new stake in Olema Pharmaceuticals during the 4th quarter valued at $1,061,000. Invesco Ltd. lifted its position in shares of Olema Pharmaceuticals by 25.0% during the fourth quarter. Invesco Ltd. now owns 155,732 shares of the company’s stock worth $3,893,000 after acquiring an additional 31,098 shares in the last quarter. Finally, EP Wealth Advisors LLC purchased a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth $250,000. Institutional investors own 91.78% of the company’s stock.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. Wolfe Research began coverage on Olema Pharmaceuticals in a research report on Friday, March 27th. They issued a “peer perform” rating for the company. Guggenheim dropped their price objective on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Jefferies Financial Group started coverage on Olema Pharmaceuticals in a research note on Thursday, March 19th. They issued a “buy” rating and a $40.00 target price for the company. Wall Street Zen raised Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday. Finally, HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Friday, May 22nd. Eleven investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.10.
Olema Pharmaceuticals Stock Performance
Olema Pharmaceuticals stock opened at $11.91 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.88 and a current ratio of 10.88. Olema Pharmaceuticals, Inc. has a fifty-two week low of $4.37 and a fifty-two week high of $36.26. The stock has a market cap of $1.04 billion, a P/E ratio of -5.90 and a beta of 2.00. The firm’s fifty day moving average price is $12.17 and its 200-day moving average price is $18.00.
Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.52). Equities research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.
About Olema Pharmaceuticals
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Featured Stories
- Five stocks we like better than Olema Pharmaceuticals
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Want to see what other hedge funds are holding OLMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report).
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
